Grifols Initiates Trial for New COVID-19 Drug
The drug offers immediate post-exposure protection against the virus and will serve as a counterpart to the vaccine during its early phases.
Grifols, a Spanish pharmaceutical and chemical manufacturer, announced on Jan. 18, 2021 that it has initiated a clinical trial in Spain to evaluate a new COVID-19 drug based on its immunoglobulin, Gamunex-C, and antibodies from plasma donors who have recovered from the disease.
According to a company press release, the drug offers immediate post-exposure protection against the virus and will serve as a counterpart to the vaccine during its early phases. Additionally, the new drug has the potential to contain COVID-19 outbreaks in areas where vaccination measures haven’t started or are still underway.
“[The drug] is easy to refrigerate while its subcutaneous administration facilitates its distribution and use in any doctor’s office, avoiding hospitalization,” said Dr. Antonio Páez, medical director at Grifols, in the press release. “If the new therapy’s efficacy is confirmed, it could be administered to people who test positive for the virus through PCR and antigen tests in hospitals and primary care offices.”
Source: Grifols
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
